By admin 
In a landmark 4-to-3 decision that carries significant implications for the pharmaceutical industry’s pricing power, the Michigan Supreme Court ruled on Friday that Attorney General Dana Nessel may proceed with a wide-ranging investigation into Eli Lilly and Co.’s pricing practices for its insulin products. The ruling effectively dismantles a lower court’s previous injunction that had stalled the state’s probe for over four years, potentially opening the floodgates for similar consumer protection inquiries into the high costs of life-saving medications.
The high court’s majority opinion represents a pivotal shift in the interpretation of Michigan’s Consumer Protection Act (MCPA), specifically addressing a long-standing "regulatory exemption" that pharmaceutical companies have historically used to shield themselves from state-level price-gouging investigations. By siding with Nessel, the court has signaled that being a federally regulated entity does not grant a "blanket immunity" from state-level scrutiny regarding unfair or unconscionable trade practices.
The investigation, which Nessel first announced in early 2022, focuses on whether the Indianapolis-based drugmaker violated state law by charging "grossly excessive" prices for three of its cornerstone insulin medications: Humalog, Basaglar, and Lispro. At the time the probe was initiated, the Attorney General’s office cited harrowing accounts of Michigan residents who were forced to ration their insulin doses, skip meals to maintain blood sugar levels, or choose between purchasing medication and paying for housing. In court filings, the state alleged that these pricing practices led to "serious disability and even death" for some diabetic patients, characterizing the drugmaker’s profit margins as being built on the backs of a captive and vulnerable population.
Eli Lilly has consistently defended its pricing, arguing that the complex ecosystem of the U.S. healthcare system—specifically the role of pharmacy benefit managers (PBMs)—is responsible for the high list prices that consumers see at the pharmacy counter. The company has maintained that it provides significant rebates and discounts that are often not passed down to the patient. Furthermore, Lilly argued in its legal defense that because its drug labels and manufacturing processes are heavily overseen by the U.S. Food and Drug Administration (FDA), it should be exempt from the Michigan Consumer Protection Act under a provision that excludes transactions "specifically authorized" by law.
However, the Michigan Supreme Court majority rejected this expansive view of the exemption. The justices noted that while the FDA regulates the safety, efficacy, and labeling of insulin, it does not "specifically authorize" the final retail price or the marketing strategies employed to maximize profit at the expense of consumer accessibility. This distinction is critical; it separates the clinical regulation of the product from the commercial conduct of the corporation, allowing the state to investigate the latter without infringing upon federal pharmaceutical oversight.
The dissenting justices, however, expressed concern that the ruling could create a "slippery slope" of litigation. They argued that the legislature intended for the MCPA to have narrow applications to avoid duplicating the work of federal regulators. The 4-3 split highlights the deep ideological divide regarding corporate accountability and state sovereignty in an era of skyrocketing healthcare costs.
To understand the weight of this ruling, one must look at the broader historical context of the insulin market. For decades, the "Big Three" insulin manufacturers—Eli Lilly, Sanofi, and Novo Nordisk—have controlled approximately 90% of the global market. Between 2002 and 2013, the list price of Humalog increased by nearly 600%, a trend that was mirrored by its competitors. While the companies argue that net prices (the amount they receive after rebates) have actually declined in recent years, those savings rarely reached the uninsured or those with high-deductible insurance plans.
The Michigan probe was initially launched during a period of intense national outcry over the "insulin cartel," a term used by activists to describe the perceived lack of competition in the space. Since then, the landscape has shifted slightly. In 2023, under immense political pressure and the looming threat of the Inflation Reduction Act’s (IRA) drug price provisions, Eli Lilly announced it would cap out-of-pocket costs for its insulin at $35 a month and slash the list prices of its most popular products by 70%.
While some industry analysts expected these voluntary price cuts to render Nessel’s investigation moot, the Attorney General has remained steadfast. Her office argues that the 2023 price reductions, while welcome, do not absolve the company of its conduct during the preceding decade. The probe seeks to uncover internal communications and financial data from the years when prices were at their peak, aiming to determine if the company engaged in deceptive practices to inflate costs or if it conspired with PBMs to maintain high list prices to secure preferential placement on insurance formularies.
Legal experts suggest that this investigation could serve as a blueprint for other states. California, Minnesota, and Washington have already launched various legal and legislative efforts to curb insulin costs, ranging from state-sponsored manufacturing of generic insulin to lawsuits against PBMs. The Michigan ruling provides a fresh legal precedent that challenges the "regulated industry" defense, which has long been a formidable barrier for state prosecutors.
"This is not just about insulin," said Sarah Jenkins, a healthcare policy analyst. "This ruling is a shot across the bow for the entire pharmaceutical industry. It suggests that if a state can prove that a drug price is ‘unconscionable’ under consumer protection statutes, the company cannot simply hide behind its FDA registration. We could see similar probes into the pricing of epinephrine injectors, asthma inhalers, and even the new class of GLP-1 weight-loss drugs."
The data surrounding the human impact of high insulin prices remains staggering. According to a 2022 study published in the Annals of Internal Medicine, nearly 1.3 million Americans with diabetes rationed their insulin due to cost. For a Type 1 diabetic, insulin is not optional; rationing can lead to diabetic ketoacidosis (DKA), a life-threatening condition. Nessel’s office has emphasized that the "grossly excessive" pricing cited in the probe is not a matter of market fluctuations, but a "market failure" that required state intervention.
Eli Lilly’s response to the ruling has been one of disappointment. In a brief statement, the company reiterated its commitment to affordability and expressed concern that the investigation would be an unnecessary and costly distraction. "We have already taken industry-leading steps to ensure that no patient is left behind," a company spokesperson said. "We believe the Attorney General’s focus would be better spent addressing the PBMs and insurers who continue to profit from high list prices while we have lowered ours."
The next phase of the investigation will likely involve a series of subpoenas for internal documents, emails, and pricing contracts. This "discovery" phase is what the pharmaceutical industry fears most. Internal documents could reveal the exact calculations used to determine price hikes and the extent to which the company coordinated its moves with competitors or middle-men in the supply chain. If the investigation finds evidence of bad faith or consumer deception, it could lead to massive fines, restitution for Michigan patients, and potentially a court-ordered restructuring of how the company prices its medications within the state.
The 2026 ruling arrives at a time when the federal government is also tightening its grip on the industry. The Inflation Reduction Act’s provision allowing Medicare to negotiate prices for certain high-cost drugs has already begun to ripple through the market. However, the IRA’s protections do not cover everyone, leaving many in the commercial market or the uninsured population vulnerable. State-level actions like Nessel’s investigation are seen as essential "gap-fillers" in the quest for universal drug affordability.
As the legal battle moves back to the lower courts and the Attorney General’s investigators begin their work, the eyes of the nation will be on Michigan. The outcome could redefine the boundaries of corporate responsibility in the healthcare sector. For the thousands of Michigan residents who have struggled to afford the medication they need to survive, the ruling is a long-awaited victory. For Eli Lilly and the broader pharmaceutical industry, it is a sobering reminder that the era of unchecked pricing power may be coming to a close.
The case, Department of Attorney General v. Eli Lilly and Co., will now return to the Ingham County Circuit Court, where the state will seek to enforce its civil investigative demands. The road ahead is likely to be paved with further motions and appeals, but for now, the Michigan Supreme Court has made one thing clear: in the pursuit of consumer protection, no company is too large to be questioned.
